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ABSTRACT New evidence on breast Magnetic Resonance Imaging (MRI) screening has 
become available since the American Cancer Society (ACS) last issued guidelines for the early 
detection of breast cancer in 2003. A guideline panel has reviewed this evidence and developed 
new recommendations for women at different defined levels of risk. Screening MRI is recom­
mended for women with an approximately 20-25%  or greater lifetime risk of breast cancer, 
including women with a strong family history of breast or ovarian cancer and women who were 
treated for Hodgkin disease. There are several risk subgroups for which the available data are 
insufficient to recommend for or against screening, including women with a personal history of 
breast cancer, carcinoma in situ, atypical hyperplasia, and extremely dense breasts on mam­
mography. Diagnostic uses of MRI were not considered to be within the scope of this review. 
(CA Cancer J  Clin 2007;57:75-89.) © American Cancer Society, Inc., 2007.
To earn free CM E c re d it fo r su c c e s s fu lly  co m p le tin g  th e  on line  qu iz  based  on th is  a rtic le , go to  
http://CM E.Am CancerSoc.org.
INTRODUCTION
Mammography has been proven to detect breast cancer at an early stage and, 
when followed up with appropriate diagnosis and treatment, to reduce mortality 
from breast cancer. For women at increased risk of breast cancer, other screening 
technologies also may contribute to the earlier detection of breast cancer, particu­
larly in women under the age of 40 years for whom mammography is less sensitive. 
The American Cancer Society (ACS) guideline for the early detection of breast can­
cer, last updated in 2003, stated that women at increased risk of breast cancer might 
benefit from additional screening strategies beyond those offered to women at aver­
age risk, such as earlier initiation o f screening, shorter screening intervals, or the 
addition o f screening modalities (such as breast ultrasound or magnetic resonance 
imaging [MRI]) other than mammography and physical examination. However, the 
evidence available at the time was insufficient to justify recommendations for any 
of these screening approaches. The ACS recommended that decisions about screen­
ing options for women at significantly increased risk of breast cancer be based on 
shared decision making after a review of potential benefits, limitations, and harms of 
different screening strategies and the degree o f uncertainty about each.1
Although there still are limitations in the available evidence, additional pub­
lished studies have become available since the last update, particularly regarding
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use of breast M RI. The ACS guide­
line panel has sought to provide addi­
tional guidance to women and their 
health care providers based on these 
new data.
GUIDELINE DEVELOPMENT
The ACS convened an expert 
panel to review the existing early 
detection guideline for women at 
increased risk and for M R I screen­
ing based on evidence that has accu­
m ulated since the last revision in 
2002 to 2003. Literature related to 
breast M R I screening published betw een  
September 2002 and July 2006 was identified 
using MEDLINE (National Library o f Medi­
cine), bibliographies of identified articles, and 
unpublished manuscripts. Expert panel mem­
bers reviewed and discussed data during a series 
of conference calls and a working meeting in 
August, 2006. W hen evidence was insufficient 
or lacking, the final recommendations incor­
porated the expert opinions of the panel mem­
bers. The ACS Breast Cancer Advisory Group 
members and the National Board o f Directors 
discussed and voted to approve the recommen­
dations.
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SUMMARY OF RECOMMENDATIONS
Table 1 summarizes the ACS recommendations 
for breast M RI screening.
BACKGROUND
MRI
MRI utilizes magnetic fields to produce detailed 
cross-sectional images of tissue structures, pro­
viding very good soft tissue contrast. Contrast 
between tissues in the breast (fat, glandular tis­
sue, lesions, etc.) depends on the mobility and 
magnetic environment of the hydrogen atoms in 
water and fat that contribute to the measured 
signal that determines the brightness of tissues 
in the image. In the breast, this results in images 
showing predominantly parenchyma and fat, and 
lesions, if they are present. A paramagnetic small 
molecular gadolinium-based contrast agent is 
injected intravenously to provide reliable detec­
tion of cancers and other lesions. Thus, contrast 
enhanced M RI has been shown to have a high 
sensitivity for detecting breast cancer in high­
risk asymptomatic and symptomatic women, 
although reports of specificity have been more 
variable.2-8 This high signal from enhancing 
lesions can be difficult to separate from fat, lead­
ing to the use o f subtraction images or fat
TABLE 1 Recommendations for Breast MRI Screening as an Adjunct to Mammography
Recommend Annual MRI Screening (Based on Evidence*)
BRCA mutation
First-degree relative of BRCA carrier, but untested
Lifetime risk ~20—25% or greater, as defined by BRCAPRO or other models that are largely dependent on family history
Recommend Annual MRI Screening (Based on Expert Consensus Opinionf)
Radiation to chest between age 10 and 30 years 
Li-Fraumeni syndrome and first-degree relatives
Cowden and Bannayan-Riley-Ruvalcaba syndromes and first-degree relatives
Insufficient Evidence to Recommend for or Against MRI Screening!
Lifetime risk 15-20%, as defined by BRCAPRO or other models that are largely dependent on family history 
Lobular carcinoma in situ (LCIS) or atypical lobular hyperplasia (ALH)
Atypical ductal hyperplasia (ADH)
Heterogeneously or extremely dense breast on mammography
Women with a personal history of breast cancer, including ductal carcinoma in situ (DCIS)
Recommend Against MRI Screening (Based on Expert Consensus Opinion )
Women at <15%  lifetime risk
*Evidence from nonrandomized screening trials and observational studies. 
fBased on evidence of lifetime risk for breast cancer.
^Payment should not be a barrier. Screening decisions should be made on a case-by-case basis, as there may be 
particular factors to support MRI. More data on these groups is expected to be published soon.
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suppression, or both, to assess disease. Because 
parenchymal tissue also enhances, but generally 
more slowly than malignant lesions, and also 
because contrast can wash out rapidly from some 
tumors, it is important to look at images at an 
early time point after contrast injection (typically
1 to 3 minutes). M RI examinations may involve 
examining images at one time point or, more 
often, will collect a preinjection image with 
sequential sets of images after contrast injection 
(dynamic contrast-enhanced [DCE]-MRI). Both 
the appearance of lesions and, where available, 
the uptake and washout pattern can be used to 
identify malignant disease and discriminate it 
from benign conditions.
These techniques, which have been widely 
employed for assessing symptomatic disease, have 
recently been shown to provide good sensitiv­
ity as a screening tool for breast cancer in women 
at increased risk based on family history.9-14 The 
approach requires appropriate techniques and 
equipment, together with experienced staff. 
Higher quality images are produced by dedi­
cated breast M RI coils, rather than body, chest, 
or abdominal coils.
IDENTIFICATION OF WOMEN WITH A
HIGH RISK OF BREAST CANCER
Three approaches are available for identify­
ing women with a high risk of breast cancer: 
family history assessment, genetic testing, and 
review of clinical history. All contribute to iden­
tifying women who are candidates for breast 
M RI screening.
Family History
Although a high proportion of women in the 
general population have at least one relative with 
breast cancer, for the majority of these women, 
this “family history” either does not increase risk 
at all (ie, the cancer was sporadic) or is associ­
ated with, at most, a doubling of lifetime risk 
(due to either shared environmental risk factors 
or an inherited gene of low penetrance). Only 
1% to 2% of women have a family history sug­
gestive of the inheritance of an autosomal dom­
inant, high-penetrance gene conferring up to 
an 80% lifetime risk o f breast cancer. In some 
families, there is also a high risk o f ovarian
cancer. Features of the family history which 
suggest the cancers may be due to such a high- 
penetrance gene include 2 or more close (gen­
erally first- or second-degree) relatives with breast 
or ovarian cancer; breast cancer occurring before 
age 50 years (premenopausal) in a close relative; 
a family history of both breast and ovarian can­
cer; one or more relatives with 2 cancers (breast 
and ovarian cancer or 2 independent breast can­
cers); and male relatives with breast cancer.15-18
Two breast/ovarian cancer susceptibility genes, 
BRCA1  and BRCA2, have been identified.19,20 
Inherited mutations in these genes can be found 
in approximately 50% of families in which an 
inherited risk is strongly suspected based on the 
frequency and age of onset of breast cancer cases, 
and in most families in which there is a much 
higher than expected incidence of both breast 
and ovarian cancer.
Several models can assist clinicians to estimate 
breast cancer risk or the likelihood that a BRCA  
m utation  is present (O nline Supplem ental 
Material). The Gail, Claus, and Tyrer-Cusick 
models estimate breast cancer risk based on fam­
ily history, sometimes in combination with other 
risk factors, such as reproductive history or prior 
breast biopsies.16,21-23 Although risk prediction 
is generally similar for the different models, an 
individual woman’s risk estimate may vary with 
different models.21,24,25
Two decision models have been developed 
to estimate the likelihood that a BRCA  mutation 
is present, BR CA PRO 18,26 and the Breast and 
Ovarian Analysis of Disease Incidence and Carrier 
Estimation A lgorithm  (BOADICEA)27; the 
BOADICEA model also provides estimates of 
breast cancer risk (Online Supplemental Material).
Genetic Testing
The prevalence of BRCA  mutations is esti­
mated to be between 1/500 and 1/1,000 in the 
general population28; however, in women ofJewish 
ethnicity, the prevalence is 1/50.29,30 Women with 
cancer-predisposing mutations in either BRCA1 
or BRCA2  have an increased risk of both breast 
and ovarian cancer. From population-based 
studies, women with BRCA1 mutations are esti­
mated to have a 65% risk by age 70 years for 
developing breast cancer (95% confidence inter­
val [CI], 44% to 78%); the corresponding risk
Volume 57 • Number 2 • March/April 2007 77
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for BRC A2  mutations is 45% (95% CI, 31% to 
56%).31 Risks estimated from cancer-prone fam­
ilies seen in referral centers are higher, with limit 
o f risk in the 85% to 90% range.31 These muta­
tions follow an autosomal dominant pattern of 
transmission, which means that the sister, mother, 
or daughter o f a woman with a BRC A  muta­
tion has a 50% chance of having the same muta­
tion.
The benefits and risks of genetic testing are 
beyond the scope of this article, but are reviewed 
in the American Society of Clinical Oncology 
policy statement update on genetic testing for 
cancer susceptibility.32 Genetic testing for a 
BRCA1 or BRCA2  mutation is generally offered 
to adult members o f families with a known 
BRC A  mutation, or to women with at least a 
10% likelihood o f carrying such a mutation, 
based on either validated family history criteria 
or one o f the above-m entioned models. If a 
woman from a family in which a BRCA  muta­
tion has been previously identified does not have 
that mutation, one can generally safely conclude 
that her breast cancer risk is no higher than it 
would have been if she did not have a family 
history of breast cancer. However, in a high-risk 
family without a known mutation, failure to 
find a mutation in a particular member does not 
reduce her risk estimate.
A high risk of breast cancer also occurs with 
mutations in the TP53 gene (Li-Fraumeni syn­
drome) and the P T E N  gene (Cow den and 
B annayan-R iley-R uvalcaba syndrom es).33 
Accurate prevalence figures are not available, but 
these conditions appear to be very rare.34,35
Clinical Indicators of Risk
Some clinical factors are associated with sub­
stantial breast cancer risk. Among women with 
Hodgkin disease, increased breast cancer risk has 
been consistently and significantly associated 
with mantle field radiation treatment. In several 
studies o f women treated between 1955 and 
1995, risk was inversely related to age at treat­
ment in patients diagnosed between the ages of 
10 to 30 years, with only slight or no increased 
risk when diagnosis was before age 10 years or 
after age 30 years.36-41 Risk following treatment 
with radiation and chemotherapy was half that 
o f  trea tm en t w ith  rad ia tion  alone in two
studies,39,42 which may reflect the effect of 
chemotherapy on earlier onset of menopause; risk 
was equivalent in a third study.43 Risk of breast 
cancer significantly increased 15 to 30 years after 
radiation therapy.41 More recently, treatment 
approaches have used lower doses of radiation and 
limited-field radiotherapy. In one study, which 
compared patients who received radiation ther­
apy in 1966 to 1974 and 1975 to 1985, treat­
ment in the later timeframe was not related to 
increased risk of breast cancer after a median 
follow up of 13 years, whereas patients treated 
between 1966 and 1974 were at increased risk, 
suggesting that Hodgkin disease survivors treated 
with current approaches will not face substan­
tially increased breast cancer risk.44
Lobular carcinoma in situ (LCIS) and atypi­
cal lobular hyperplasia (ALH), together described 
as lobular neoplasia, are associated with substan­
tially increased risk of subsequent breast cancer, 
with lifetime risk estimates ranging from 10% 
to 20%.45 This equates to a continuous risk of 
about 0.5% to 1.0% per year. The invasive can­
cers may be ipsilateral or contralateral, are usu­
ally invasive lobular cancers, and more than 50% 
of these diagnoses occur more than 15 years after 
the original diagnosis of LCIS. Similar findings 
have been reported by Fisher et al,46 describing 
a 12-year update of 180 women with LCIS who 
were treated with local excision alone and fol­
lowed by the National Surgical Adjuvant Breast 
Project (NSABP), as well as Li et al, who de­
scribed the risk of invasive breast cancer among 
4,490 LCIS patients using Surveillance, Epidemi­
ology, and End Results (SEER) data between 
1988 to 2001.47
Atypical ductal hyperplasia (ADH) is part of 
the continuum of ductal proliferative breast dis­
eases ranging from usual ductal hyperplasia to 
ductal carcinoma in situ (DCIS). The literature 
review by Arpino et al45 suggests a 4- to 5-fold 
increased risk o f invasive breast cancer (com­
pared with a 6- to 10-fold risk with LCIS) at a 
median follow up of 17 years, which is doubled 
if the woman has an associated family history of 
breast cancer. It is unclear, however, what per­
centage of the women with this family history 
and ADH are at this significantly increased risk 
because they are carriers of a BRCA1  or 2 gene 
mutation.
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Mammographic density has been shown to 
be a strong independent risk factor for the devel­
opment of breast cancer.48-51 In several studies, 
women with the most breast density were found 
to have a 4- to 6-fold increased risk of breast can­
cer, compared with women with the least dense 
breasts.52-56 For example, women with 75% or 
higher mammographic density had a more than 
five-fold increased risk of breast cancer, com­
pared with women with less than 1% density.57 
In addition, it has been shown that malignant 
tumors of the breast are more likely to arise in 
the areas of greatest mammographic density, com­
pared with the more fatty areas of the breast.58
The absolute risk of contralateral breast can­
cer in women with a personal history of breast 
cancer is estimated to be 0.5% to 1% per year, or 
5% to 10% during the 10 years following diag­
nosis, significantly higher than that of the gen­
eral population.59 H orm one therapy an d /o r 
chemotherapy for the primary cancer is likely 
to subsequently lower the risk o f contralat­
eral breast cancer.
EVIDENCE AND RATIONALE
Evidence of Efficacy from MRI Screening Studies
In the mid to late 1990s, at least 6 prospective, 
nonrandomized studies were initiated in The 
Netherlands, the United Kingdom (UK), Canada, 
Germany, the United States (US), and Italy to 
determine the benefit of adding annual M RI to 
(film) mammography for women at increased 
risk of breast cancer. Some of the studies included 
ultrasound and/or clinical breast examination, 
as well. Despite substantial differences in patient 
population (age, risk, etc.) and M RI technique, 
all reported significantly higher sensitivity for 
M RI compared with mammography (or any of 
the other modalities). All studies that included 
more than one round of screening reported inter­
val cancer rates below 10%. Participants in each 
of these 6 studies had either a docum ented 
BRCA1  or BRC A2  mutation or a very strong 
family history of breast cancer. Some of the stud­
ies included women with a prior personal his­
tory of breast cancer.
Kriege et al screened 1,909 unaffected women 
aged 25 to 70 years with an estimated 15% or
higher lifetime risk of breast cancer (19% proven 
to have a BRC A  mutation) at 6 centers across 
The Netherlands.9 After a median of 3 rounds of 
screening, 50 breast cancers (44 invasive) were 
diagnosed. Eighty percent of the invasive can­
cers were detected by MRI, compared with 33% 
by mammography. However, mammography 
outperformed M RI for detecting DCIS. O f the 
invasive cancers, 43% were 1 cm or smaller in 
diameter, and 33% had spread to axillary lymph 
nodes. The specificity of M RI was 90%, com­
pared with 95% for mammography.
Leach et al screened 649 unaffected women 
aged 35 to 49 years who had at least a 25% life­
time risk of breast cancer (19% proven to have a 
BRCA  mutation) at 22 centers in the UK.11 After 
a median of 3 rounds o f screening, 35 cancers 
(29 invasive) were diagnosed. Sensitivity of MRI 
was 77%, compared with 40% for mammography, 
with specificities of 81% and 93%, respectively. 
M RI was most sensitive and mammography least 
sensitive for women with BRCA1  mutations. 
Forty-five percent of the cancers were 1 cm or less 
in size, and 14% had spread to axillary lymph 
nodes. There were two interval cancers.
Warner et al screened 236 women aged 25 
to 65 years with a BRCA  mutation at a single 
center in Toronto for up to 3 years and detected 
22 cancers (16 invasive).14 Sensitivity o f M RI 
was 77%, compared with 36% for mammogra­
phy, with 50% of the cancers 1 cm or smaller, 
and 13% were node positive. There was one 
interval cancer. Specificity was 95% for M RI 
and 99.8% for mammography.
Kuhl et al screened 529 women aged 30 years 
and older with a lifetime breast cancer risk of at 
least 20% at a single center in Bonn for a mean of
5 years.10 They detected 43 cancers (34 invasive), 
with 1 interval cancer. The sensitivity of M RI 
was 91%, compared with 33% for mammogra­
phy. The node positive rate was 16%. Specificity 
of both M RI and mammography was 97%.
The International Breast M RI Consortium 
screened 390 women aged 25 years and older 
with more than a 25% lifetime risk of breast can­
cer at 13 centers (predominantly in the US) on 
a single occasion.12 Four cancers were found by 
M RI, and only one of these by mammography. 
However, because the patients were not followed 
after screening, the false-negative rate could not
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TABLE 2 Published Breast MRI Screening Study Results
The Netherlands Canada United Kingdom Germany United States Italy
No. of centers 6 1 22 1 13 9
No. of women 1,909 236 649 529 390 105
Age range 25-70 25-65 35-49 > 30 > 25 > 2 5
No. o f cancers 50 22 35 43 4 8
Sensitivity (%)
MRI 80 77 77 91 100 100
Mammogram 33 36 40 33 25 16
Ultrasound n/a 33 n/a 40 n/a 16
Specificity (%)
MRI 90 95 81 97 95 99
Mammogram 95 > 99 93 97 98 0
Ultrasound n/a 96 n/a 91 n/a 0
n/a = not applicable.
be determined. M RI specificity was 95%, com­
pared with 98% for mammography.
In a study in Italy with 9 participating centers, 
Sardanelli et al screened 278 women aged 25 years 
and older; 27% carried a BRC A  mutation or 
had a first-degree relative with a BRC A  muta­
tion.13 After a median o f 1.4 rounds of screen­
ing, 18 cancers (14 invasive) were found. M RI 
sensitivity was 94%, compared with 59% for 
mammography, 65% for ultrasound, and 50% 
for clinical breast examination. M RI specificity 
was 99%.
Overall, studies have found high sensitivity 
for MRI, ranging from 71% to 100% versus 16% 
to 40% for mammography in these high-risk 
populations. Three studies included ultrasound, 
which had sensitivity similar to mammography. 
The Canadian, Dutch, and UK studies9,11,14 
reported similar sensitivity (71% to 77%) within 
CIs for M RI, although the single-center study 
from Germany10 reported a higher sensitivity, 
which may reflect the concentration o f radio­
logical practice and higher patient volume per 
radiologist at a single center. There is evidence of 
a learning curve for radiologists conducting MRI 
breast screening, with the number of lesions inves­
tigated falling with experience.60 The three mul­
ticenter studies reflect the likely initial effectiveness 
of this modality in a population context, and it 
is expected that, with training and advances in 
technology, sensitivity will increase further.
Table 2 provides a summary of these six screen­
ing studies.
Most of the available data are based on screen­
ing women at high risk due to family history
and/or genetic mutations. More recently, smaller 
studies have provided information on the poten­
tial benefit of M RI screening for women with 
clinical factors that put them at increased risk. 
Preliminary data were obtained from one retro­
spective study, in which Port et al61 reviewed 
the screening results o f252 women with biopsy- 
confirmed LCIS and 126 women with atypical 
hyperplasia (either ductal or lobular), of whom 
half were screened with annual mammography 
and biennial clinical exams and half were also 
screened with M RI. The women who were 
screened with M R I were younger and more 
likely to have a strong family history. MRI screen­
ing offered a small advantage to patients with 
LCIS, but not atypical hyperplasia, and also 
resulted in increased biopsies: 6 cancers were 
detected by M RI in 5 women with LCIS (4% of 
patients undergoing M R I), and none were 
detected in women with atypical hyperplasia. 
Biopsies were recommended for 25% of M RI 
screened patients; 13% of biopsies had a cancer 
detected. All of the cancers in women screened 
with M RI were Stage 0 to I, whereas all of the 
cancers in women who were not screened with 
M RI were Stage I to II. Cancer was detected 
on the first M RI in 4 of 5 patients. The sensi­
tivity of M RI was 75%, the specificity was 92%, 
and the positive predictive value was 13%.
Technological Limitations and Potential Harms
Associated with MRI Screening
A lthough the efficacy o f breast M R I has 
been demonstrated, it does not achieve perfect
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TABLE 3 Rates of Detection and Follow-up Tests for Screening MRI Compared with Mammography
MRI Mammography
The Netherlands United Kingdom The Netherlands United Kingdom
Positives 13.7% 19.7% 6.0% 7.2%
Recalls 10.84% 10.7% 5.4% 3.9%
Biopsies 2.93% 3.08% 1.3% 1.33%
Cancers 1.04% 1.44% 0.46% 0.69%
False negatives 0.23% 0.43% 0.81% 1.52%
sensitivity or specificity in women undergo­
ing screening, and as such, the issue o f adverse 
consequences for women who do, but espe­
cially those who do not, have breast cancer is 
important to address. As with mammography 
and other screening tests, false negatives after 
M R I screening can be attributed to inherent 
technological limitations of M RI, patient char­
acteristics, quality assurance failures, and human 
error; false positives also can be attributed to 
these factors, as well as heightened medical- 
legal concerns over the consequence o f missed 
cancers. A patient’s desire for definitive find­
ings in the presence of a low-suspicion lesion 
may also contribute to a higher rate of benign 
biopsies. The consequences o f all these fac­
tors include missed cancers, with potentially 
worse prognosis, as well as anxiety and poten­
tial harms associated w ith interventions for 
benign lesions.
The specificity of M RI is significantly lower 
than that of mammography in all studies to date, 
resulting in more recalls and biopsies. Call-back 
rates for additional imaging ranged from 8% to 
17% in the M RI screening studies, and biopsy 
rates ranged from 3% to 15%.9-14 However, sev­
eral researchers have reported that recall rates 
decreased in subsequent rounds o f screening: 
prevalence screens had the highest false-positive 
rates, which subsequently dropped to less than 
10%.9,62,63 Most call backs can be resolved with­
out biopsy. The call-back and biopsy rates of 
M RI are higher than for mammography in high­
risk populations; while the increased sensitivity 
of M RI leads to a higher call-back rate, it also 
leads to a higher number of cancers detected. 
The proportion of biopsies that are cancerous 
(positive predictive value) is 20% to 40%.9-14 
Since false-positive results appear to be common,
more data are needed on factors associated with 
lower specificity rates.
Table 3 compares the likelihood of detection 
and follow-up tests for women who underwent 
screening M R I and m am m ography in two 
screening studies (Dutch and UK). The study 
populations differed, with the Dutch study hav­
ing a wider age group and lower risk category, 
compared with the UK study.9,11 This affected 
both the prevalence of cancer and the pick-up 
rate by modality in the two studies. These results, 
drawn from two trials, demonstrate the rela­
tively high recall rate in the high-risk popula­
tion, as well as the fact that M RI is a relatively 
new technique. Despite the high num ber of 
recalls, because of the high cancer rate, the rate 
of benign surgical biopsy in the UK study per 
cancer detected was similar to that experienced 
in the population-based national breast screen­
ing service. Recalls will inevitably lead to addi­
tional investigations, many of which will not 
demonstrate that cancer is present.
Given the high rate of cancer combined with 
the risk of false-positive scans in a high-risk pop­
ulation undergoing MRI-based screening, the 
psychological health of these women merits 
study. In a subgroup of 611 women in the UK 
study, 89% reported that they definitely intended 
to return for further screening, and only 1% def­
initely intended not to return. However, 4% 
found breast M RI “extremely distressing,” and 
47% reported still having intrusive thoughts about 
the examination 6 weeks afterward.64
In a sample o f 357 women from the Dutch 
study, psychological distress remained within 
norm al limits throughout screening for the 
group as a whole. However, elevated breast 
cancer-specific distress related to screening was 
found in excessive (at least once per week) breast
Volume 57 • Number 2 • March/April 2007 a J
D
ow
nloaded 
from 
caonline.am
cancersoc.org 
by 
on 
February 
5, 2009 
(©
A
m
erican 
C
ancer 
Society, 
Inc.)
American Cancer Society Guidelines fo r  Breast Screening with M R I  as an Adjunct to Mammography
self-examiners, risk overestimators, and women 
closely involved in the breast cancer case of a sis­
ter. At least 35% of the total sample belonged 
to one of these subgroups. It was recommended 
that patients in one o f these vulnerable sub­
groups be approached for additional psycho­
logical support.65
In a small sample of women from the Toronto 
study followed over a course of 2 years, there 
was no evidence of any effect on global anxiety, 
depression, or breast cancer-related anxiety.66 In 
another sample of 57 women, almost 50% had 
elevated baseline general and/or breast cancer- 
specific anxiety, but in 77% of cases this was 
attributed by the patients to life events, includ­
ing relatives with cancer. A nonsignificant increase 
in general anxiety and breast cancer-related anx­
iety, compared with baseline, was found in the 
subset of women recalled for further imaging or 
biopsies.67 Follow-up time is still insufficient to 
determine whether anxiety scores return to base­
line once the work up has been completed.
There is a special responsibility to alert 
patients to this technology, with its potential 
strengths and harms, and to be encouraging, 
while allowing for shared decision making. The 
interplay between risks, benefits, limitations, 
and harms is complicated by the fact that indi­
vidual women likely will weigh these differ­
ently depending on their age, values, perception 
of risk, and their understanding of the issues. 
Steps should be taken to reduce anxiety asso­
ciated with screening and the waiting time to 
diagnosis, and conscientious efforts should be 
made to inform women about the likelihood 
of both false-negative and false-positive find­
ings. How information is conveyed to the patient 
greatly influences the patient’s response: it is 
important that providers not convey an undue 
sense of anxiety about a positive M RI finding. 
W hile the high rate o f biopsies and further 
investigations is acceptable in women with a 
high risk of breast cancer, the number of such 
investigations in women at lower risk will be 
much higher than would be appropriate, lead­
ing to the need to counsel women in lower 
risk categories that M RI screening is not advis­
able and that the harms are believed to out­
weigh the benefits. Such advice needs to be 
based on considerations of family history, genetic
m utation status, other risk factors, age, and 
mammographic breast density.
There are substantial concerns about costs of 
and limited access to high-quality M RI breast 
screening services for women with familial risk. 
In addition, MRI-guided biopsies are not widely 
available. W ith many communities not provid­
ing M RI screening and with MRI-guided biop­
sies not widely available, it is recognized that 
these recommendations may generate concerns 
in high-risk women who may have limited access 
to this technology.
The ability of M R I to detect breast cancer 
(both invasive and in situ disease) is directly related 
to high-quality imaging, particularly the signal- 
to-noise ratio, as well as spatial resolution of the 
M R  image. In order to detect early breast can­
cer (ie, small invasive cancers, as well as DCIS), 
simultaneous imaging of both breasts with high 
spatial resolution is favored. High spatial resolu­
tion imaging should be performed with a breast 
coil on a high field magnet with thin slices and 
high matrix (approximately 1 mm in-plane res­
olution). These technical parameters are consid­
ered to be the minimal requirements to perform 
an adequate breast M RI study. The ability to per­
form MRI-guided biopsy is absolutely essential 
to offering screening MRI, as many cancers (par­
ticularly early cancers) will be identified only on 
M R I. The Am erican College o f Radiology 
(ACR) is currently developing an accreditation 
process for performing breast MRI, and, in addi­
tion to the performance of high spatial resolu­
tio n  im ages, the ab ility  to  p e rfo rm  M R I 
intervention (ie, needle localization and/or biopsy) 
will be essential in order to obtain accreditation 
by this group. Accreditation will be voluntary 
and not mandatory. This guideline will likely be 
available in 2007.
There is a learning curve with respect to inter­
pretation for radiologists. Published trial sites 
that experience a high volume of cases are expe­
rienced, but community practice groups have 
reported call-back rates over 50% in the major­
ity of the studies that are interpreted. Experience 
and familiarity with patterns of enhancement, 
normal and possibly abnormal, are thought to 
decrease recall rates and increase positive biopsy 
rates. The A CR accreditation process will stip­
ulate a minimum number of exams that must be
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read for training purposes and a minimum num­
ber for ongoing accreditation. Sites performing 
breast M RI are encouraged to audit their call­
back rates, biopsy rates, and positive biopsy rates.
Cost-effectiveness
Only limited data are available on the cost- 
effectiveness of breast M RI screening. One recent 
study modeled cost-effectiveness for adding MRI 
to mammography screening for women of dif­
ferent age groups w ho carry a B R C A 1  or 
BRCA2  mutation.68 The authors concluded that 
the cost per quality-adjusted life year (QALY) 
saved for annual M RI plus film mammography, 
compared with annual film mammography alone, 
varied by age and was more favorable in carri­
ers o f  a m utation  in B R C A 1  than B R C A 2  
because BRCA1  mutations confer higher can­
cer risk, and higher risk of more aggressive can­
cers, than BRC A2  mutations.31 Estimated cost 
per QALY for women aged 35 to 54 years was 
$55,420 for women with a BRCA1  mutation 
and $130,695 for women with a BRCA2  muta­
tion. Cost-effectiveness was increased when the 
sensitivity of mammography was lower, such as 
in women with very dense breasts on mammog­
raphy: estimated costs per QALY were $41,183 
for women with a BRCA1 mutation and $98,454 
for women with a BR_CA2 mutation with dense 
breast tissue. The most important determinants 
o f cost-effectiveness were breast cancer risk, 
mammography sensitivity, M RI cost, and qual­
ity of life gains from MRI.
An evaluation of the cost-effectiveness of the 
UK study69 has determined that the incremen­
tal cost per cancer detected for women at approx­
imately 50% risk o f carrying a B R C A  gene 
mutation was $50,911 for M RI combined with 
mammography over mammography alone. For 
known mutation carriers, the incremental cost 
per cancer detected decreased to $27,544 for 
M RI combined with mammography, compared 
with mammography alone. Analysis supporting 
the introduction of targeted M RI screening in 
the UK for high-risk women70 identified the 
incremental cost of combined screening per 
QALY in 40- to 49-year-old women as $14,005 
for a BRCA1  carrier with a 31% 10-year risk— 
the group in which M RI screening is seen to 
be most effective; $53,320 for women with a
12% 10-year risk; and $96,379 for women with 
a 6% 10-year risk. For the 30- to 39-year-old 
age range, the incremental costs per QALY are 
$24,275 for a B R C A 1  carrier w ith an 11% 
10-year risk and $70,054 for a women with a 
5% 10-year risk. Based on these estimates, which 
are based on costs within the UK National Health 
Service, M RI screening will be offered to women 
at familial risk aged 30 to 39 years at a 10-year 
risk greater than 8%, and to women at familial 
risk aged 40 to 49 years at a 10-year risk greater 
than 20%, or greater than 12% when mammog­
raphy has shown a dense breast pattern.
Evidence Supporting Benefit of MRI Screening
Among Women in Different Risk Categories
The guideline recommendations were based 
on consideration of (1) estimates of level of risk 
for women in various categories and (2) the extent 
to which risk groups have been included in M RI 
studies, or to which subgroup-specific evidence 
is available. Because of the high false-positive rate 
of M RI screening, and because women at higher 
risk of breast cancer are much more likely to ben­
efit than women at lower risk, screening should 
be recommended only to women who have a 
high prior probability of breast cancer. There is 
growing evidence that breast cancer in women 
with specific mutations may have biological and 
histological features that differ from sporadic can­
cers. This may result in observed variations in 
the sensitivity of M RI relative to mammogra­
phy in detecting cancer in women with a BRCA  
mutation and those at high familial risk, but with­
out mutations in these genes.11
Women at Increased Risk Based on
Family History
The threshold for defining a woman as hav­
ing significantly elevated risk of breast cancer is 
based on expert opinion. Any woman with a 
BR_CA1 or BR_CA2 mutation should be con­
sidered at high risk. The panel has not restricted 
its recommendations only to women with BRCA  
mutations because BRC A  testing is not always 
available or informative, and other risk indica­
tors identify additional subsets of women with 
increased breast cancer risk. If mutation testing 
is not available, has been done and is noninfor­
mative, or if a woman chooses not to undergo
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TABLE 4 Breast Cancer Risks for Hypothetical Patients, Based on 3 Risk Models
American Cancer Society Guidelines fo r  Breast Screening with M R I  as an Adjunct to Mammography
Family History BRCAPRO*18 Claust16 Tyrer-CuzickJ23
35-year-old woman 
Mother BC 33 
Maternal aunt BC 42 19% 36% 28%
35-year-old woman 
Paternal aunt BC 29, OC 49 
Paternal grandmother BC 35 23% 24% 32%
35-year-old woman 
Paternal aunt BC 29 
Paternal grandmother BC 35 18% 24% 31%
35-year-old woman 
Mother BC 51 
Maternal aunt BC 60 13% 18% 23%
35-year-old woman o f Jewish ancestry 
Mother BC 51 
Maternal aunt BC 60 18% 18% 28%
BC = breast cancer.
OC = ovarian cancer.
*BRCAPRO (1.4-2) Breast cancer risk calculated to age 85 years. 
fBreast cancer risk calculated to age 79 years.
JBreast cancer risk calculated for lifetime. Other personal characteristics included in the Tyrer-Cuzick risk model for each 
case were age at menarche = 12; age at first birth = 28; height = 1.37 meters (5 feet, 4 inches); weight = 61 kg (134 lbs); 
woman has never used hormone replacement therapy (HRT); no atypical hyperplasia or lobular carcinoma in situ (LCIS).
testing, pedigree characteristics suggesting high 
risk may be considered. Very careful family his­
tory analysis is required, using tools such as 
BRCAPRO.18,26 Risk assessment is likely to offer 
the greatest potential benefit for women under 
the age of 40 years. Table 4 provides examples of 
women with a family history indicative of mod­
erate and high risk. The online supplemental 
material provides guidance for accessing and 
using risk assessment models.
Women at Increased Risk Based
on Clinical Factors
Additional factors that increase the risk of breast 
cancer, and thus may warrant earlier or more fre­
quent screening, include previous treatment with 
chest irradiation (eg, for Hodgkin disease), a per­
sonal history of LCIS or ADH, mammographi- 
cally dense breasts, and a personal history of breast 
cancer, as discussed above. There are little data to 
assess the benefit of M RI screening in women 
with these risk factors. Women at increased risk 
or who are concerned about their risk may find 
it helpful to have their provider clarify the bases
for M RI screening recommendations, as well as 
areas of uncertainty. For some women, mammog­
raphy may be as effective as for women at average 
risk, and M RI screening may have little added 
benefit. In contrast, mammography is less effec­
tive in women with very dense breasts, and MRI 
screening may offer added benefit.
Women who have received radiation treat­
ment to the chest, such as for Hodgkin disease, 
compose a well-defined group that is at high risk. 
Although evidence of the efficacy of M RI screen­
ing in this group is lacking, it is expected that 
M RI screening might offer similar benefit as for 
women with a strong family history, particularly 
at younger ages and within 30 years of treatment. 
Because of the high risk of secondary breast can­
cer in this group, M RI screening is recommended 
based on expert consensus opinion.
While lifetime risk of breast cancer for women 
diagnosed with LCIS may exceed 20%, the risk 
o f invasive breast cancer is continuous and only 
moderate for risk in the 12 years following local 
excision.46 Only one M RI screening study has 
included a select group of women with LCIS,61
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which showed a small benefit over mammogra­
phy alone in detecting cancer. This benefit was 
not seen in patients with atypical hyperplasia. 
M RI use should be decided on a case-by-case 
basis, based on factors such as age, family his­
tory, characteristics of the biopsy sample, breast 
density, and patient preference.
A lthough there have been  several trials 
reported looking at the accuracy and positive 
predictive value of M RI and mammography in 
women with high breast density, all of these tri­
als have been conducted in women with known 
or highly-suspected malignancies w ithin the 
breast.71-74 To this point, there has been no Phase 
III randomized trial reported that has shown a 
reduction in either mortality or in the size of 
diagnosed breast cancer when comparing breast 
M RI with mammography in women with high 
mammographic density.
Scant data are available for M RI screening of 
women with a personal history of breast cancer. 
In one study, M R I detected more cancers in 
women who had both a personal history and a 
family history, compared with women at high 
risk based on family history alone.75 While women 
with a previous diagnosis of breast cancer are at 
increased risk o f a second diagnosis, the ACS 
panel concluded that the estimated absolute life­
time risk of 10% does not justify a recommenda­
tion for M RI screening at the present time.
Limitations of Evidence from MRI Studies
and Research Needs
Assiduous attempts were made to base rec­
ommendations on solid evidence. However, out­
come data from screening M RI studies are not 
sufficient to form a solid basis for many of the rec­
ommendations. It was therefore necessary to rely 
on available inferential evidence and expert opin­
ion to provide the guidance needed for patients 
and their health care providers.
Although the literature shows very good evi­
dence for greater sensitivity of M RI than mam­
mography and good evidence for a stage shift 
toward earlier, more favorable tumor stages by 
M RI in defined groups of women at increased 
risk, there are still no data on recurrence or 
survival rates, and therefore, lead-time bias is 
still a concern. Further, a large randomized, mor­
tality endpoint study is unlikely to take place,
and it will be necessary in the foreseeable future 
to rely on evidence of stage of disease and types 
of cancers. In the absence of randomized trials, 
recurrence and survival data will come from 
observational study designs.
The age at which screening should be initi­
ated for women at high risk is not well estab­
lished. The argument for early screening is based 
on the cumulative risk of breast cancer in women 
with BRCA1 mutations and a strong family his­
tory of early breast cancer, which is estimated 
to  be 3% by age 30 years and 19% by age 
40 years.76 Population-based data also indicate 
that risk for early breast cancer is increased by a 
family history of early breast cancer.16 Based on 
these observations, some experts have suggested 
that breast cancer screening begin 5 to 10 years 
before the earliest previous breast cancer in the 
family. In 1997, an expert panel suggested that 
screening be initiated at some time between the 
ages o f 25 and 35 years for w om en w ith  a 
BRCA1  or BRC A2  mutation.77 Because these 
recommendations were based on limited obser­
vational data, the decision regarding when to 
initiate screening should be based on shared deci­
sion making, taking into consideration individ­
ual circumstances and preferences. No data are 
available related to the effectiveness of screening 
women beyond age 69 years with M R I and 
mammography versus mammography alone; 
most of the current data are based on screening 
in younger women, and thus, similar investiga­
tions are needed in older age cohorts. For most 
women at high risk, screening with M RI and 
mammography should begin at age 30 years and 
continue for as long as a woman is in good health.1
Most of the available data are based on annual 
MRI screening; there is a lack of evidence regard­
ing shorter or longer screening intervals. Further, 
while good data are available for the first screen­
ing exam (ie, the “prevalent screen”), consider­
ably less data are available from  subsequent 
screening exams (ie, “incidence screens”), and 
the available data include relatively short follow- 
up times. Most studies of annual MRI have shown 
few interval cancers, certainly fewer than with 
mammography. Given the probably shorter dura­
tion of the detectable preclinical phase, or sojourn 
time, in women with BRCA  mutations, M RI 
has demonstrated superiority to mammography
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in this regard. Therefore, to the best of our knowl­
edge, M R I should be perform ed annually. 
However, in view of data suggesting that tumor 
doubling time in women with an inherited risk 
decreases with age,78 it is conceivable that older 
women can safely be screened less frequently than 
younger women. The available evidence is lim­
ited, and additional research regarding optimal 
screening interval by age and risk status is needed.
Some experts recommend staggering M RI 
screening and mammography screening every
6 m onths. The po ten tia l advantage o f  this 
approach is that it may reduce the rate of inter­
val cancers. O ther experts recommend M RI 
and mammography at the same time or within 
a short time period. This approach allows for 
the results o f both screening tests to be inter­
preted together and reported to the patient at 
the same time. All of the clinical trials screened 
participants with both M RI and mammogra­
phy at the same time. There is no evidence to 
support one approach over the other. For the 
majority of women at high risk, it is critical that 
M RI screening be provided in addition to, not 
instead of, mammography, as the sensitivity and 
cancer yield of M RI and mammography com­
bined is greater than for M RI alone. However, 
where there is a concern about raised radiation 
sensitivity, it may be advisable to employ M RI 
alone despite the overall lower sensitivity.
In order to pursue answers to some o f the 
unresolved questions related to the use of M RI 
and mammography to screen women at increased 
risk, it is important to develop creative strategies 
related to data gathering and study design. 
Multicenter studies can result in greater efficiency 
in accumulating sufficiently large enough data 
sets in this subgroup of women. Conventional 
study designs with randomization may prove dif­
ficult given the potential advantage o f adding 
M RI to mammography in higher-risk groups, 
and thus, design strategies that utilize surrogate 
markers and historic controls may prove both 
more practical and feasible. To move forward, 
we encourage the development of a simple, com­
mon data collection protocol to capture infor­
mation from the growing number of centers that 
offer M RI and formal systems to collect out­
come data. Because many insurers presently cover 
M RI screening for high-risk women, it may be
economical to do prospective surveillance stud­
ies since screening costs are covered by third par­
ties. A comm on surveillance protocol could 
permit pooling of data, much like presently is 
done w ithin the framework o f the National 
Cancer Institute’s Breast Cancer Surveillance 
Consortium, a collaborative network of seven 
mammography registries in the United States 
with linkages to tumor and/or pathology reg­
istries that was organized to study the delivery and 
quality o f breast cancer screening and related 
patient outcomes in the United States.79 We also 
encourage seeking opportunities for broad inter­
national research collaboration on study ques­
tions of common interest.
Several further clinical trials of screening women 
at increased risk of breast cancer are underway, 
including an international study o f M R I and 
ultrasound in conjunction with the International 
Breast M RI Consortium and Cancer Genetics 
Network, and the American College of Radiology 
Imaging Network (ACRIN) 666 screening trial 
of mammography compared with ultrasound. 
An amendment to the ACRIN trial, 6666, will 
screen patients with one round of MRI.
CONCLUSION
O ften no available screening m odality is 
uniquely ideal. For breast MRI, there is an increas­
ing body of observational data showing that screen­
ing can identify cancer in patients of specific risk 
groups, ie, high-risk patients facing a lifetime risk 
of~20-25% or greater related to family history as 
estimated by one or more o f the different risk 
models. We have specified a range of risk because 
estimates from the risk models vary and because 
each of the risk models is imperfect. Furthermore, 
these models likely will continue to be refined 
over time; therefore, these risk estimates for dif­
ferent family history profiles are likely to change. 
Thus, when estimating patient risk it is impor­
tant to always be certain that the most current 
model is being used. In addition to family his­
tory, clinical factors as described earlier may be a 
relevant factor in individualized decisions about 
MRI screening when family history alone does not 
predict a risk of approximately 20-25%.
Several studies have demonstrated the ability 
o f M RI screening to detect cancer with early-
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stage tumors that are associated with better out­
comes. While survival or mortality data are not 
available, M RI has higher sensitivity and finds 
smaller tumors, compared with mammography, 
and the types o f cancers found with M RI are 
the types that contribute to reduced mortality. 
It is reasonable to extrapolate that detection of 
noninvasive (DCIS) and small invasive cancers 
will lead to mortality benefit.
The guideline recommendations for M RI 
screening as an adjunct to mammography for 
women at increased risk of breast cancer take 
into account the available evidence on efficacy 
and effectiveness of M RI screening, estimates 
of level of risk for women in various categories 
based on both family history and clinical fac­
tors, and expert consensus opinion where evi­
dence for certain risk groups is lacking. All of 
these groups of women should be offered clin­
ical trials of M RI screening, if available. Women 
should be informed about the benefits, limita­
tions, and potential harms o f M RI screening, 
including the likelihood of false-positive find­
ings. Recommendations are conditional on an 
acceptable level o f quality of M RI screening, 
which should be performed by experienced 
providers in facilities that provide MRI-guided 
biopsy for the follow up of any suspicious results.
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Erratum
In the March/April 2007 issue, in the article “American Cancer Society Guidelines for Breast 
Screening with M RI as an Adjunct to Mammography” (CA Cancer J  Clin 2007;57:75-89), an 
error appeared in the text on page 86. The sentence that read, “However, in view of data sug­
gesting that tumor doubling time in women with an inherited risk decreases with age,78 it is con­
ceivable that older women can safely be screened less frequently than younger women” was 
incorrect. It should read, “However, in view of data suggesting that tumor doubling time in 
women with an inherited risk increases with age,78 it is conceivable that older women can safely 
be screened less frequently than younger women.” The authors regret the error and apologize 
for any confusion it may have caused.
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